Latest research: initiation, Nov 20, 2026 · Market value $315,600m
UNHSellTarget $297.81−12% expected
Our view, Nov 20, 2026
UnitedHealth still trades at a premium its peers and margins cannot support
UnitedHealth insures 48 million Americans and owns the clinics, pharmacies and software those members use. Earnings are recovering, but at peers’ multiple the shares are worth about $266, not $350.
Value per share in each case
Circle size shows how likely we think each case is. Case values are today’s values; the target rolls the weighted $282.39 forward 12 months. Source: Penmark Research.
For FY26E we forecast earnings per share of $20.73, against analysts’ $20.59. For FY27E we forecast earnings per share of $23.52, against analysts’ $23.29.
Our earnings per share forecasts against analysts’
Our estimateAnalysts’ forecast
Earnings per share as the report gives them. Analysts’ forecast is the consensus figure in the report. Source: Penmark Research estimates.
Downside: medical trend tops pricing and UHC margin falls back to 3.0%: −$40.78 a share (20% probability).
Downside: DOJ Medicare Advantage coding probes cut the P/E to 10.5x: −$23.52 a share (20% probability).
Upside risk: restoring the 8.65% FY20 to FY25 median margin lifts value to $374.06 (+$107.70 a share), a Buy.
What bulls get right. Earnings are recovering and our 2027 EPS is above the Street. If margins return to the 8.65% historical median, the value rises to $374.06, a Buy.
Dates to watch
Insurers challenge the 2018 to 2027 audit extrapolation.
We expect $2.39 of Q4 EPS, a 91.0% ratio and $23.52 for 2027.
Draft 2028 rates; tight chart-review curbs would cost $1.67 a share.
Penmark Research rates UnitedHealth Group (UNH) Sell, with a 12-month price target of $297.81, -15% from the $349.91 share price at our latest report. We expect a total return worse than −10% over the next 12 months: a fall of more than 10%, after dividends.
What is the UNH price target?
Our 12-month price target for UnitedHealth Group is $297.81, set in our initiation of Nov 20, 2026. Our bear case values the shares at $168.75 and our bull case at $428.07. The target comes from the probability-weighted value of our bull, base and bear cases.
Will UnitedHealth Group stock go up?
Our UnitedHealth Group stock forecast is a 12-month price target of $297.81, -15% from the $349.91 share price at our latest report, which is why we rate it Sell. Our bear case puts the shares at $168.75 (-52%) and our bull case at $428.07 (+22%). No forecast is certain; the main risks are below.
What does UnitedHealth Group do?
UnitedHealth Group runs UnitedHealthcare, the largest US health insurer, and Optum’s clinics, health IT and Optum Rx pharmacy benefit manager.
What are the main risks to UnitedHealth Group stock?
Downside: medical trend tops pricing and UHC margin falls back to 3.0%: −$40.78 a share (20% probability).
Downside: DOJ Medicare Advantage coding probes cut the P/E to 10.5x: −$23.52 a share (20% probability).
Upside risk: restoring the 8.65% FY20 to FY25 median margin lifts value to $374.06 (+$107.70 a share), a Buy.
What is Penmark’s latest research on UnitedHealth Group?
Our latest report is our initiation of Nov 20, 2026, “Initiate at Sell with a $298 target as peer valuation caps the recovery”. We initiate on UnitedHealth Group at Sell (low conviction) with a $297.81 target, a −12.2% total return from $349.91. Buyers pay 14.9x our FY27E adjusted EPS of $23.52; restating managed-care peers for UNH’s growth and returns gives 11.5x, which cuts $95 a share. Margins rebuild to 6.3% in FY27E but stay below the…